Eli Lilly, Pfizer celebrate a PhIII success for their blockbuster pain drug contender tanezumab -- but questions linger
Five years after Eli Lilly stepped up with a $1.8 billion deal to bring Pfizer’s anti-NGF pain drug tanezumab back from limbo, the pharma giants are reporting that they successfully navigated a major Phase III study for the non-opioid therapy among patients suffering from osteoarthritis.
Researchers say that their drug hit three primary endpoints for pain, physical function and the patients’ overall assessment of their OA. Tapped by Pfizer as one of the leading late-stage drugs in their pipeline, the investigators also noted that “rapidly progressive osteoarthritis was observed in tanezumab-treated patients at a frequency of less than 1.5%, and was not observed in the placebo arm.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
